WHO Grade III Glioma Recruiting Phase 2 Trials for Sildenafil (DB00203)

IndicationStatusPhase
DBCOND0089571 (WHO Grade III Glioma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01817751Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade GliomaTreatment